Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Nextech Invest is a biotechnology investment firm based in Zurich, Switzerland, founded in 1998. The firm has established itself as one of the longest-running dedicated oncology venture capital firms in Europe. With a strong commitment to supporting emerging biotechnology companies globally, Nextech Invest focuses on transformative cancer medicines that can significantly impact patient outcomes.
Currently, Nextech Invest manages approximately $616 million in assets under management (AUM) across multiple fund vehicles. The firm operates from its headquarters in Zurich and has additional offices in Boston and San Francisco. This geographical presence allows Nextech Invest to engage with a diverse range of biotechnology companies, particularly in North America and Europe.
Over the years, Nextech Invest has achieved notable milestones, including a track record of 17 successful exits, which underscores its credibility as a repeat successful oncology backer. The firm actively participates in key industry events, such as the ASCO Annual Meeting and the J.P. Morgan Healthcare Conference, to stay connected with the biotech community.
Nextech Invest specializes in investments within the biotechnology sector, with a particular emphasis on precision medicine and oncology. The firm targets companies at various stages of development, from pre-seed to Series C, allowing them to support startups through critical moments of scientific validation and company growth. Their investment strategy is centered on identifying first and best-in-class targeted therapies that can address significant unmet medical needs.
The firm seeks to partner with founders who are developing innovative therapies, particularly those focused on cancer treatment. Nextech Invest provides not only capital but also deep scientific diligence and access to a cancer-research advisory board comprised of experts from top academic centers. This support enhances the chances of success for portfolio companies navigating the complexities of drug development.
Nextech Invest's portfolio includes a diverse range of biotechnology companies, reflecting its commitment to nurturing innovative therapies in the oncology space. Notable companies in their portfolio include:
This portfolio showcases Nextech Invest's dedication to supporting companies that are at the forefront of biotechnology innovation.
Karl-Heinz Altmann, Ph.D. - Science Partner. He brings extensive experience in biotechnology and has a strong background in scientific research and development.
Alexis Borisy - Chairman. Borisy has a notable track record in the biotech industry, having led several successful ventures and investments.
Thilo Schroeder, Ph.D. - Managing Partner. Schroeder specializes in oncology investments and has a deep understanding of the biotechnology landscape.
Benjamin Cravatt, Ph.D. - Science Partner. Cravatt focuses on emerging cancer therapies and has a strong scientific background in drug development.
Rocco Sgobbo - Managing Partner, COO. Sgobbo oversees operations and strategic initiatives at Nextech Invest, contributing to the firm's overall success.
To pitch Nextech Invest, founders should utilize the investor portal available on their website. It is essential to include a comprehensive pitch deck that outlines the technology, market opportunity, competitive landscape, and team qualifications. While specific response times are not disclosed, founders are encouraged to provide detailed information to facilitate a thorough evaluation.
Warm introductions are preferred, as they can enhance the likelihood of a favorable review. Founders should aim to demonstrate how their innovations align with Nextech Invest's focus on oncology and precision medicine.
In January 2025, Nextech Invest participated in a Series C funding round for Be Biopharma, contributing to a total of $92 million raised. This investment highlights Nextech's ongoing commitment to supporting innovative biotechnology companies.
The firm continues to deploy capital from its active fund, Nextech VIII, which focuses on oncology investments. Recent reports indicate that Nextech Invest is actively seeking new opportunities in the biotechnology sector, particularly those aligned with their investment thesis.
What investment criteria does Nextech Invest prioritize?
Nextech Invest focuses on biotechnology companies, particularly those developing innovative therapies in oncology and precision medicine. They look for startups that demonstrate strong scientific validation and have the potential to address significant unmet medical needs.
How can founders pitch to Nextech Invest?
Founders can pitch their ideas through the Nextech Invest website, where they provide a dedicated investor portal. It is recommended to include detailed information about the technology, market potential, and the team in the pitch deck.
What makes Nextech Invest different from other venture capital firms?
Nextech Invest distinguishes itself through its deep scientific diligence and access to a cancer-research advisory board comprised of experts from leading academic institutions. This unique support structure enhances the chances of success for portfolio companies.
What is the geographic scope of Nextech Invest's investments?
The firm invests globally, with a strong focus on North America and Europe. Their portfolio reflects this geographic diversity, with companies based in both regions.
What is the typical check size for investments made by Nextech Invest?
While specific check sizes are not disclosed, Nextech Invest participates in funding rounds across various stages, from pre-seed to Series C, indicating a flexible investment approach tailored to the needs of the companies they support.
What kind of post-investment involvement does Nextech Invest have?
Nextech Invest engages actively with its portfolio companies, providing mentorship, operational support, and access to their advisory board to help navigate the complexities of drug development and commercialization.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.